SII, DNDi in pact to develop affordable dengue treatment
New Delhi, June 13 (UNI) The Serum Institute of India (SII), the world's largest vaccine manufacturer and Drugs for Neglected Diseases initiative (DNDi), a not-for-profit research entity, have entered into a partnership with an aim to accelerate the development of a monoclonal antibody treatment for dengue fever.
The initiative specifically targets low- and middle-income countries (LMICs), where dengue is endemic and health systems are often under strain during outbreaks, said a joint statement here from the organisations.
Despite the rising global burden of dengue — with an estimated 3.9 billion people at risk and cases more than doubling annually since 2021 — there is currently no specific treatment available. The new monoclonal antibody candidate, previously known as VIS513, has shown promise in pre-clinical studies and early-phase clinical trials led by SII, demonstrating safety and efficacy, added the statement.
The SII is currently leading a pivotal Phase III clinical trial in India, while SII and DNDi will now work together to conduct additional Phase III trials in other dengue-endemic countries, including Brazil, Malaysia and Thailand, it added.
The two entities will work jointly to implement research and development activities, raise necessary resources, and build strategies for regulatory approval and equitable access.
Dr Kavita Singh, Director of South Asia and Asia Continental Lead at DNDi, noted, 'Dengue is no longer confined to historically endemic areas. Its spread into newer regions makes it imperative to invest in both preventive and therapeutic solutions'
She said climate change is altering patterns for dengue fever and other diseases. "Before, we didn't have as many cases, or as many deaths,' she added.
Dr Prasad Kulkarni, executive director of SII, was of the opinion that this move would help advancing the clinical development of a dengue monoclonal antibody not only in India, but also in Brazil and other countries in Southeast Asia. Our aim is to make this treatment affordable and widely accessible.'
Since the start of 2025, more than 3 million dengue cases and over 1,400 dengue-related deaths have been reported across 90 countries in the WHO Regions of the America, South-East Asia, the Western Pacific, Eastern Mediterranean, and Africa.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
India Gazette
33 minutes ago
- India Gazette
Serum Institute of India holds 'Conquer HPV and Cancer Conclave' in Visakhapatnam
Visakhapatnam (Andhra Pradesh) [India], June 14 (ANI): Serum Institute of India (SII) held the 'Conquer HPV and Cancer Conclave' in Visakhapatnam, Andhra Pradesh, to spread awareness regarding the sexually transmitted infection Human Papillomavirus (HPV). Dr B. Murli Santosh, consultant paediatrician and neonatologist, attended the conclave on Friday. Speaking to reporters, he said, '...Cervical cancer is the second most common cancer in Indian women, not only Indian women, across the globe, and annually, as per the statistics, close to 1,00,000 deaths are reported in India.' Emphasising the HPV vaccine, he added, 'So one thing that the public needs to know is that there is a vaccine by which we can prevent this cancer and which has been readily available for the last 10 to 15 years. But the problem in India is that the awareness among the public... various reasons, cost constraints, or various misconceptions. The amount of vaccinations which the public are getting is very less. Now we are having Indian-made vaccines which are easily available and cost-effective. And once we can effectively vaccinate, this cancer is almost hundred per cent preventable. So, most of the time, we recommend early-age vaccinations, preferably at 9 to 14 years, in which they receive two doses, and at 15 to 45 years, in which they receive three doses. And once they receive the vaccination, most of the time they get 99% to 100% protection against these cancers.' Speaking to ANI, Dr R Vidya Rama, professor of obstetrics and gynaecology in Andhra Medical College and the visiting consultant, Medicover Women and Child Hospitals, said, 'We have gathered here to talk about HPV vaccination. What are the recent changes in HPV vaccination? Previously this vaccination was advocated for girls to prevent cervical cancer, but now it's been proven that HPV is not only for cervical cancer but also for cancers in men, it is penile cancer, and it is also a cause for anal cancers and oropharyngeal cancers in both men and women.' Elaborating on vaccination, Dr Rama said, 'So ideally, the vaccination to prevent these cancers should be given before sexual exposure. The best time to take the vaccine is between 9 and 14 years. When the immune response and protection will be maximum, and only two doses would be enough. But, if the girls and boys miss out their vaccination at the age below 15 years, they can take the vaccination even after 15 years. Previously, we had a vaccine made by an MNC only, which is a very effective and safe vaccine, but the only disadvantage with that particular vaccine is costly. Now we have a vaccine, a quadrivalent vaccine, which has been made by the Serum Institute of biggest advantage is we have a vaccine which comes with a very affordable cost that is very important for our country to protect our girls and boys with a vaccine.' SII, in collaboration with India's Department of Biotechnology (DBT) and Biotechnology Industry Research Assistance Council (BIRAC), recently developed India's first indigenous gender neutral quadrivalent HPV vaccine, Cervavac. The medical firm is holding a nationwide conclave to spread awareness regarding the vaccine. (ANI)
United News of India
5 hours ago
- United News of India
AP: Serum Institute launches nationwide HPV-Cancer public awareness campaign
Visakhapatnam, June 13 (UNI) : The 'Conquer HPV & Cancer Conclave 2025' was launched here on Friday as part of a nationwide public health initiative by Pune-based Serum Institute of India Pvt. Ltd, part of Cyrus Poonawalla Group is a global leader in vaccine manufacturing. India continues to face a significant burden of HPV-related diseases, particularly cervical cancer, which remains the second most common cancer among women in the country. According to the ICO/IARC Information Centre on HPV and Cancer (2023), India reports over 1.23 lakh new cervical cancer cases and more than 77,000 related deaths annually. Apart from this up to 90 percent of anal cancers & 63 percent of penile cancers are associated with HPV. At the Visakhapatnam event, a panel of medical specialists engaged in an in-depth discussion about the public health implications of HPV. The panel included Dr. Sunanda Rani Gutta – Director & Chief Consultant Gynaecologist, Nikitha Hospital, Visakhapatnam; Dr. Redla Vidya Rama – Prof. of Obstetrics & Gynecology, Andhra Medical College and King George Hospital; Dr. Sai Sunil Kishore Manem – Chief Neonatologist, Medicover Hospital, Vizag. Associate Professor MIMS Medical College, Vizianagaram and Dr. Buddha Murali Santosh – MBBS, DNB, fellowship in Neonatology. Gold medalist. Neonatologist and Pediatrician at Motherly Women and Children Hospital, Vizag The session was moderated by Dr. Vani Isukapalli – Superintendent, King George Hospital, Visakhapatnam. President-IMA, Visakhapatnam. Together, they highlighted the pressing need for awareness, the importance of reaching both adolescents and parents, and the role of healthcare providers in guiding preventive care. The speakers emphasized that HPV is not limited to cervical cancer alone. It is also associated with cancers of the vulva, vagina, anus, penis, and oropharynx, affecting both men and women. With peak HPV infection occurring between ages 15 to 25, early awareness and timely preventive action are essential. With an affordable HPV vaccine now available, it has become still more easier to protect every individual from HPV associated cancers. 'Through these conclaves held across the country, we aim to increase understanding of Human Papillomavirus (HPV) and its link to cervical and other cancers,' said Parag Deshmukh, Executive Director, Serum Institute of India. 'By bringing together medical experts, healthcare workers, and community members, the forum encourages open dialogue and practical steps toward early detection and prevention,' he said. The Visakhapatnam conclave concluded with an open dialogue involving audience members, reinforcing the broader goal of the campaign: to reduce the burden of preventable cancers through informed decision-making and community engagement. The initiative will continue in cities across the country in the coming months, creating platforms for credible voices in healthcare to educate and empower the public. UNI KNR SSP
Hindustan Times
6 hours ago
- Hindustan Times
Serum, DNDi to develop affordable dengue treatment
Serum Institute of India (SII) on Friday signed a memorandum of understanding (MoU) with not-for-profit medical research organisation Drugs for Neglected Diseases initiative (DNDi) to accelerate clinical development of a monoclonal antibody treatment for dengue that will be affordable and accessible in low-and middle-income countries (LMICs). SII and DNDi will develop a work plan to implement research and development, Phase 3 clinical trials, and access activities, along with a joint strategy to raise the necessary funds and resources. SII stated that it has already conducted pre-clinical studies and Phase 1 and 2 clinical trials that show the candidate is safe and effective. It is currently leading the Phase 3 clinical trial in India for licensure. The Pune-based company said a joint project team will be formed to advance clinical trials, with the goal of registering and deploying the dengue monoclonal antibody in India and other countries, provided the studies confirm its safety and efficacy.
